Innovative Cell Platform RoslinCT has a proven track record of developing and manufacturing advanced cell and gene therapies, including pioneering work with pluripotent stem cells and CRISPR-edited treatments. This positions them as a key partner for biotech firms seeking high-quality, cutting-edge manufacturing solutions for innovative therapies.

Strategic Collaborations Recent collaborations with major biotech companies like Vertex Pharmaceuticals highlight RoslinCT’s capability to support large-scale, complex projects from development through commercialization, making them an attractive contract manufacturing organization for companies aiming to bring transformative therapies to market.

Global Presence With facilities in Edinburgh and Massachusetts, RoslinCT offers a global footprint that can meet international manufacturing demands, providing potential clients with scalable, location-flexible production options for their cell therapy products.

Strong Leadership & Talent The appointment of prominent industry leaders and scientific experts indicates RoslinCT’s commitment to innovation and operational excellence, which can assure potential clients of reliable, top-tier development and manufacturing support.

Growth Potential ROSCLINCT’s revenues range from 50 to 100 million dollars, with recent strategic hires and a merger with Lykan Bioscience, suggest ongoing expansion and investment in capabilities—presenting sales teams with opportunities to position their solutions as part of a growing, industry-leading organization.